All In Biotech

Free tool

FAERS Monitor: Alymsys

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761231 or its brand name (Alymsys, Bevacizumab-Maly). Reports on generic versions are filed under their own applications.

Reports

201

Serious

176

88% of reports

Hospitalization

59

Death reported

38

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death17
  • asthenia15
  • nausea11
  • neutropenia11
  • decreased appetite10
  • weight increased9
  • fatigue8
  • encephalitis7
  • mucosal inflammation7
  • weight decreased7
  • aspartate aminotransferase increased6
  • blood alkaline phosphatase increased6
  • gamma-glutamyltransferase increased6
  • somnolence6
  • thrombocytopenia6

Reports by year received

View as table
YearReports
202234
202341
202423
202542
202661

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,958 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
encephalitisSignal7106.051.2626
gamma-glutamyltransferase increasedSignal628.312.9132
mucosal inflammationSignal728.013.5156
blood alkaline phosphatase increasedSignal625.311.5117
aspartate aminotransferase increasedSignal611.85.449
neutropeniaSignal118.54.866
thrombocytopeniaSignal65.62.618
decreased appetiteSignal104.52.524
weight increasedSignal94.22.219
astheniaSignal154.22.634
somnolenceSignal63.11.47
weight decreasedSignal72.61.36
deathSignal172.11.39
nausea111.50.81
fatigue81.10.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.